Based on data from the ONWARDS clinical trial program, the manufacturer submitted a biologics license application (BLA) for once-weekly insulin icodec for the treatment of diabetes mellitus to the US Food & Drug Administration (FDA) and to the European Medicines Agency (EMA) in April and May 2023, respectively [16,17]. This evidence concerns the gene INS and diabetes mellitus.